Inhaled PT005

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

COPDChronic Obstructive Pulmonary Disease

Phase 1

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00880490

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2008-11-30End: 2009-05-31Updated: 2010-10-13

Phase 2

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

WithdrawnNCT01043601

Pearl Therapeutics, Inc.COPD

Start: 2010-07-31End: 2011-04-30Updated: 2014-07-11

Related Papers

A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.

2014-07-0310 citations